Skip to main content
main-content

Zeitschrift

Investigational New Drugs

Investigational New Drugs 3/2018

Ausgabe 3/2018

Inhaltsverzeichnis ( 20 Artikel )

08.11.2017 | PRECLINICAL STUDIES | Ausgabe 3/2018 Open Access

Contribution of reactive oxygen species to the anticancer activity of aminoalkanol derivatives of xanthone

Daniel Sypniewski, Natalia Szkaradek, Tomasz Loch, Anna M. Waszkielewicz, Agnieszka Gunia-Krzyżak, Daria Matczyńska, Dagna Sołtysik, Henryk Marona, Ilona Bednarek

08.11.2017 | PRECLINICAL STUDIES | Ausgabe 3/2018

Cyclodextrin polymers as nanocarriers for sorafenib

Valentina Giglio, Maurizio Viale, Vittorio Bertone, Irena Maric, Rita Vaccarone, Graziella Vecchio

17.11.2017 | PRECLINICAL STUDIES | Ausgabe 3/2018

ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors

Mark C. de Gooijer, Levi C. M. Buil, Jos H. Beijnen, Olaf van Tellingen

15.11.2017 | PRECLINICAL STUDIES | Ausgabe 3/2018

LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice

Kazim Sahin, Mehmet Tuzcu, Mehmet Yabas, Cemal Orhan, Nurhan Sahin, Ibrahim H. Ozercan

18.11.2017 | PRECLINICAL STUDIES | Ausgabe 3/2018

The sirtuin 1/2 inhibitor tenovin-1 induces a nonlinear apoptosis-inducing factor-dependent cell death in a p53 null Ewing’s sarcoma cell line

Christian Marx, Lisa Marx-Blümel, Nora Lindig, René Thierbach, Doerte Hoelzer, Sabine Becker, Susan Wittig, Roland Lehmann, Hortense Slevogt, Thorsten Heinzel, Zhao-Qi Wang, James F. Beck, Jürgen Sonnemann

21.09.2017 | PHASE I STUDIES | Ausgabe 3/2018 Open Access

A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors

Neeraj Gupta, Steven Zhang, Sandeepraj Pusalkar, Mihaela Plesescu, Swapan Chowdhury, Michael J. Hanley, Bingxia Wang, Cindy Xia, Xiaoquan Zhang, Karthik Venkatakrishnan, Dale R. Shepard

19.10.2017 | PHASE I STUDIES | Ausgabe 3/2018

Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer

Shumei Kato, Denis L. Jardim, Faye M. Johnson, Vivek Subbiah, Sarina Piha-Paul, Apostolia M. Tsimberidou, Gerald S. Falchook, Daniel Karp, Ralph Zinner, Jennifer Wheler, Filip Janku, Siqing Fu, JoAnn Lim, Stacie Bean, Ly Nguyen, Susan Urban, Elsa Browne, Funda Meric-Bernstam, David S. Hong

30.09.2017 | PHASE I STUDIES | Ausgabe 3/2018

Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors

Tomohiro Nishina, Shunji Takahashi, Ryota Iwasawa, Hidehisa Noguchi, Masayuki Aoki, Toshihiko Doi

02.10.2017 | PHASE I STUDIES | Ausgabe 3/2018

Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer

Priyanka Bhateja, Afshin Dowlati, Neelesh Sharma

09.10.2017 | PHASE I STUDIES | Ausgabe 3/2018

Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results

A phase I clinical trial
Dana B. Cardin, Laura W. Goff, Emily Chan, Jennifer G. Whisenant, G. Dan Ayers, Naoko Takebe, Lori R. Arlinghaus, Thomas E. Yankeelov, Jordan Berlin, Nipun Merchant

23.02.2018 | PHASE II STUDIES | Ausgabe 3/2018

A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC)

Pedro Barata, Matthew Cooney, Allison Tyler, John Wright, Robert Dreicer, Jorge A. Garcia

06.03.2018 | PHASE II STUDIES | Ausgabe 3/2018

A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer

Laura Graham, Kalyan Banda, Alba Torres, Brett S. Carver, Yu Chen, Katie Pisano, Greg Shelkey, Tracy Curley, Howard I. Scher, Tamara L. Lotan, Andrew C. Hsieh, Dana E. Rathkopf

12.03.2018 | PHASE II STUDIES | Ausgabe 3/2018

Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study

Xavier García del Muro, Joan Maurel, Javier Martínez Trufero, Javier Lavernia, Antonio López Pousa, Ramón de las Peñas, Ricardo Cubedo, José Pablo Berros, Antonio Casado Herráez, Ana de Juan, Javier Martín Broto

27.11.2017 | PHASE III STUDIES | Ausgabe 3/2018

Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial

Emiliano Calvo, Analia Azaro, Jordi Rodon, Luc Dirix, Manon Huizing, Francis Mark Senecal, Patricia LoRusso, Lorrin Yee, Italo Poggesi, Jan de Jong, Spyros Triantos, Youn C. Park, Roland E. Knoblauch, Trilok V. Parekh, George D. Demetri, Margaret von Mehren

17.02.2018 | PHASE III STUDIES | Ausgabe 3/2018

Drug approval based on randomized phase 3 trials for relapsed malignancy: analysis of oncologic drugs granted accelerated approval, publications and clinical trial databases

Sumimasa Nagai, Keiya Ozawa

01.12.2017 | SHORT REPORT | Ausgabe 3/2018

Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin

Hyungwoo Cho, Changhoon Yoo, Kyu-pyo Kim, Jae Ho Jeong, Jihoon Kang, Heung-Moon Chang, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Sung Koo Lee, Myung-Hwan Kim, Han Chu Lee, Young-Suk Lim, Kang Mo Kim, Ju Hyun Shim, Shin Hwang, Gi-Won Song, Deok-Bog Moon, Jae Hoon Lee, Young-Joo Lee, Baek-Yeol Ryoo

18.12.2017 | SHORT REPORT | Ausgabe 3/2018

Everolimus induced mood changes in breast cancer patients: a case-control study

Olivier Mir, Alexandre Salvador, Sarah Dauchy, Stanislas Ropert, Cédric Lemogne, Raphaël Gaillard

16.01.2018 | SHORT REPORT | Ausgabe 3/2018

Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report

Kenta Ogawa, Jiro Ito, Daichi Fujimoto, Mari Morita, Yuko Yoshizumi, Koichi Ariyoshi, Keisuke Tomii, Nobuyuki Katakami

20.02.2018 | SHORT REPORT | Ausgabe 3/2018

Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report

Michael W. van Kalleveen, Maudy Walraven, Mathijs P. Hendriks

08.03.2018 | SHORT REPORT | Ausgabe 3/2018

A call for improved transparency in financial aspects of clinical trials: a case study of the CREATE-X trial in the New England Journal of Medicine

Akihiko Ozaki, Morihito Takita, Tetsuya Tanimoto

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise